loading
Precedente Chiudi:
$4.14
Aprire:
$3.99
Volume 24 ore:
26,185
Relative Volume:
0.22
Capitalizzazione di mercato:
$231.34M
Reddito:
$34.16M
Utile/perdita netta:
$-98.43M
Rapporto P/E:
-1.7863
EPS:
-2.34
Flusso di cassa netto:
$-119.33M
1 W Prestazione:
-5.64%
1M Prestazione:
-10.68%
6M Prestazione:
-46.68%
1 anno Prestazione:
-30.45%
Intervallo 1D:
Value
$3.99
$4.30
Intervallo di 1 settimana:
Value
$3.88
$4.42
Portata 52W:
Value
$2.9448
$10.25

Foghorn Therapeutics Inc Stock (FHTX) Company Profile

Name
Nome
Foghorn Therapeutics Inc
Name
Telefono
617-586-3100
Name
Indirizzo
500 TECHNOLOGY SQUARE, CAMBRIDGE
Name
Dipendente
112
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-07
Name
Ultimi documenti SEC
Name
FHTX's Discussions on Twitter

Confronta FHTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
FHTX
Foghorn Therapeutics Inc
4.1504 240.25M 34.16M -98.43M -119.33M -2.34
Biotechnology icon
ONC
Beigene Ltd Adr
241.99 24.41B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
434.89 111.55B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.31 42.47M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
587.31 63.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.77 5.92B 0 -153.72M -103.81M -2.00

Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-23 Iniziato Citizens JMP Mkt Outperform
2025-01-30 Iniziato B. Riley Securities Buy
2024-09-03 Iniziato Jefferies Buy
2024-08-19 Iniziato Evercore ISI Outperform
2023-03-28 Iniziato BofA Securities Buy
2023-01-05 Iniziato BMO Capital Markets Outperform
2021-11-22 Iniziato H.C. Wainwright Buy
2020-11-17 Iniziato Cowen Outperform
2020-11-17 Iniziato Goldman Buy
2020-11-17 Iniziato Morgan Stanley Overweight
2020-11-17 Iniziato Wedbush Outperform
Mostra tutto

Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie

pulisher
May 22, 2025

Foghorn Therapeutics Inc. to Participate in Major Upcoming Healthcare Conferences in 2025 - Nasdaq

May 22, 2025
pulisher
May 22, 2025

Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences - GlobeNewswire

May 22, 2025
pulisher
May 20, 2025

10,895 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Acquired by Cubist Systematic Strategies LLC - Defense World

May 20, 2025
pulisher
May 19, 2025

(FHTX) Trading Report - news.stocktradersdaily.com

May 19, 2025
pulisher
May 19, 2025

Q2 EPS Estimate for Foghorn Therapeutics Cut by Analyst - Defense World

May 19, 2025
pulisher
May 19, 2025

Wedbush Expects Weaker Earnings for Foghorn Therapeutics - Defense World

May 19, 2025
pulisher
May 17, 2025

JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics (NASDAQ:FHTX) - Defense World

May 17, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates - MSN

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Fog - GuruFocus

May 15, 2025
pulisher
May 15, 2025

FHTX: JMP Securities Reiterates Market Outperform Rating for Foghorn Therapeutics | FHTX Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Foghorn Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 15, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update - GlobeNewswire

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics: Pioneering Precision Medicine with Innovative Pharmacology and AI Integration - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

FHTX Exceeds Revenue Expectations and Advances Pipeline Programs - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances FHD-909 Phase 1 Trial - TipRanks

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. SEC 10-Q Report - TradingView

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Foghorn Therapeutics Advances Cancer Drug Pipeline with Strong Financial Results: Phase 1 Trial Shows Promise - Stock Titan

May 14, 2025
pulisher
May 13, 2025

Foghorn Therapeutics Inc. (NASDAQ:FHTX) Holdings Boosted by Wells Fargo & Company MN - Defense World

May 13, 2025
pulisher
May 13, 2025

Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) PT at $12.13 - Defense World

May 13, 2025
pulisher
May 12, 2025

Ted Myles Joins Cellarity as Chief Executive Officer - Stock Titan

May 12, 2025
pulisher
May 12, 2025

Barclays PLC Increases Stock Position in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 12, 2025
pulisher
May 08, 2025

(FHTX) Trading Advice - news.stocktradersdaily.com

May 08, 2025
pulisher
May 07, 2025

Renaissance Technologies LLC Acquires 22,500 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 07, 2025
pulisher
May 06, 2025

Foghorn Therapeutics’ SWOT analysis: chromatin pioneer’s stock faces clinical hurdles - Investing.com Nigeria

May 06, 2025
pulisher
May 05, 2025

Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference - GlobeNewswire

May 05, 2025
pulisher
May 03, 2025

Foghorn Therapeutics (FHTX) Expected to Announce Quarterly Earnings on Monday - Defense World

May 03, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Purchases 45,565 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

May 03, 2025
pulisher
May 02, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Buy Rating from HC Wainwright - Defense World

May 02, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics expands board with biotech veterans - Investing.com

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Elects Neil Gallagher, M.D., Ph.D., and Stuart Duty to Board of Directors - Nasdaq

May 01, 2025
pulisher
May 01, 2025

Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors - GlobeNewswire

May 01, 2025
pulisher
Apr 29, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Geode Capital Management LLC Boosts Stake in Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

FHTX Unveils Promising Preclinical Data at Cancer Research Confe - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents Preclinical Data at AACR 2025 - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update | FHTX Stock News - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update - The Manila Times

Apr 28, 2025
pulisher
Apr 28, 2025

Foghorn Therapeutics Presents New Preclinical Data on - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

Breakthrough Cancer Drug FHD-909 Shows Synergy with Leading Treatments in Lung Cancer Studies - Stock Titan

Apr 28, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Research Coverage Started at JMP Securities - Defense World

Apr 26, 2025
pulisher
Apr 26, 2025

Foghorn Therapeutics (NASDAQ:FHTX) Earns Mkt Outperform Rating from Analysts at Citizens Jmp - Defense World

Apr 26, 2025
pulisher
Apr 23, 2025

This PayPal Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Apr 23, 2025
pulisher
Apr 23, 2025

JMP Securities Initiates Coverage of Foghorn Therapeutics (FHTX) with Market Outperform Recommendation - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Targ - GuruFocus

Apr 23, 2025
pulisher
Apr 23, 2025

Foghorn Therapeutics (FHTX) Gains Outperform Rating with $9 Target | FHTX Stock News - GuruFocus

Apr 23, 2025
pulisher
Apr 18, 2025

Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World

Apr 18, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting | FHTX Stock News - GuruFocus

Apr 15, 2025

Foghorn Therapeutics Inc Azioni (FHTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.16
price down icon 17.27%
$31.18
price down icon 3.94%
$578.71
price down icon 0.54%
$286.48
price down icon 0.94%
$4.10
price down icon 2.24%
$72.94
price down icon 0.11%
Capitalizzazione:     |  Volume (24 ore):